NCT07469917 Safety Planning Intervention in Swedish Healthcare: A Multisite Study for Suicide Prevention
| NCT ID | NCT07469917 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Skane |
| Condition | Suicide Attempt |
| Study Type | INTERVENTIONAL |
| Enrollment | 8,000 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2028-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 8,000 participants in total. It began in 2025-10-01 with a primary completion date of 2028-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Suicide is one of the leading causes of premature death and a prioritized public health concern. Safety Planning Intervention (SPI) is a method with strong international research support for reducing suicidal behaviour by enhancing individuals' strategies for crisis management and improving access to support. SPI is a single-session intervention lasting approximately 45 minutes, which any healthcare provider can deliver after a brief training. Despite promising results, the implementation of SPI in Swedish healthcare remains limited. This project examines how SPI can be integrated into various healthcare settings and evaluates its impact on suicide-related emergency visits, psychiatric hospitalizations, and healthcare utilization. Data and Methods Stepped-Wedge implementation study in specialist psychiatry, where SPI is gradually introduced in psychiatric units. This study design allows for a robust evaluation of effects while ensuring all units eventually receive the intervention. As part of this study, a survey among healthcare professionals will be conducted to assess their experiences with feasibility, usability, and implementation barriers. Data will be collected from QlikView healthcare utilization data. Poisson regression models with mixed effects will be used to analyze the impact of SPI on emergency visits and psychiatric hospitalizations. A health economic analysis will be conducted to evaluate the cost-effectiveness of SPI. Societal Relevance and Impact The project contributes to Sweden's national suicide prevention strategy by: 1. Scientifically evaluating the feasibility and effects of SPI in Swedish healthcare. 2. Developing training programs for healthcare professionals in suicide prevention. 3. Informing policy decisions and national guidelines. 4. Analyzing the cost-effectiveness of SPI from a societal perspective. Implementation The research team includes experts in suicide prevention, psychiatry, epidemiology, patient safety, and health economics, creating a strong multidisciplinary foundation. The Stepped-Wedge design ensures an ethically and methodologically sound evaluation of SPI. Gradual implementation allows for time-based comparisons, minimizes selection bias, and ensures all patients receive the intervention. The project is conducted in close collaboration with healthcare providers and policymakers to ensure that research findings can be integrated into clinical practice and strengthen suicide prevention efforts in Sweden.
Eligibility Criteria
Inclusion Criteria: Patients presenting to psychiatric services with suicidal ideation, suicidal planning, or a suicide attempt Patients receiving care in participating adult psychiatric emergency or inpatient units Exclusion Criteria: Age under 18 years
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07469917 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Suicide Attempt. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07469917 currently recruiting?
Yes, NCT07469917 is actively recruiting participants. Contact the research team at sara.lindstrom@med.lu.se for enrollment information.
Where is the NCT07469917 trial being conducted?
This trial is being conducted at Helsingborg, Sweden, Kristianstad, Sweden, Lund, Sweden, Malmö, Sweden.
Who is sponsoring the NCT07469917 clinical trial?
NCT07469917 is sponsored by Region Skane. The trial plans to enroll 8,000 participants.